Tocilizumab decreases CETP activity by ~22% in 16 patients with rheumatoid arthritis (J Clin Lipidol 2026)

Original title: Tocilizumab enhances HDL functionality in rheumatoid arthritis: A 6-month prospective study on cardiovascular risk modulation

J Clin Lipidol · 31 August 2026 · 4

Gómez Rosso L, Botta E, Pierini F, Martín M, Soledad Sáez M, Davico B, Cerda O, Citera G, Gandino I, Rosa J, Kontush A, Soriano ER et al.

Prospective observational study of 16 women with rheumatoid arthritis initiating tocilizumab. Over 6 months, IL-6 receptor blockade reduced disease activity and inflammation while CETP activity decreased by ~22%. HDL functional metrics improved, including cholesterol efflux capacity rising by ~16% and free-cholesterol uptake from TGRL lipolysis increasing by ~40%. Antioxidant properties also improved, with paraoxonase-1 and antioxidant reaction activities increasing by ~12% and ~11%, respectively. These mechanistic shifts toward favorable lipoprotein quality require long-term randomized studies to determine translation into reduced cardiovascular events.

Original abstract

Background: Rheumatoid arthritis (RA) confers elevated cardiovascular risk, partly driven by dysfunctional lipoproteins and oxidative stress. Interleukin-6 (IL-6) inhibition with tocilizumab may modify lipid profiles and enhance high-density lipoprotein (HDL) functionality, potentially influencing cardiometabolic risk.

Objective: To evaluate the impact of IL-6 receptor blockade with tocilizumab on lipid profile and HDL functionality in patients with RA over a 6-month follow-up.

Methods: Prospective observational study in 16 female patients with RA initiating tocilizumab treatment. Assessments were conducted at baseline and 6 months. Clinical activity (Disease Activity Score in 28, Health Assessment Questionnaire [HAQ]), inflammatory markers, lipid profile, lipoprotein(a) [Lp(a)], oxidized low-density lipoprotein (oxLDL), paraoxonase-1 activities (PON and ARE), cholesteryl ester transfer protein (CETP) activity, HDL cholesterol efflux capacity, and HDL free-cholesterol uptake during triglyceride-rich lipoprotein (TGRL) lipolysis were measured.

Results: Tocilizumab significantly reduced disease activity and inflammation, with 87% of patients achieving remission and improved HAQ scores. Total cholesterol, low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (HDL-C), and HDL-C increased, whereas Lp(a) decreased. HDL functional metrics improved: cholesterol efflux capacity rose by ∼16%, and free-cholesterol uptake from TGRL lipolysis increased by ∼40% (P < .05). CETP activity decreased by ∼22%. Antioxidant properties improved, with PON and ARE activities increasing by ∼12% and ∼11%, respectively, and oxLDL decreasing by ∼11%.

Conclusion: After 6 months of IL-6 blockade, patients exhibited profound suppression of inflammation and enhanced HDL cardioprotective functions despite rises in LDL-C. Improvements in cholesterol efflux, TGRL-cholesterol handling, and antioxidant activity suggest a shift toward more favorable lipoprotein quality. Long-term and randomized studies are needed to determine whether these mechanistic changes translate into reduced cardiovascular events.

Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 26 September 2026. Methods.